Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for CagriSema versus 11.8% with ...

It is connected to a larger transaction in which Novo Nordisk’s controlling shareholder Novo Holdings will buy Catalent for $16.5 billion, or $63.50 per share, ...

View the latest Novo Nordisk A/S (NOVO.B) stock price, news, historical charts, analyst ratings and financial information from WSJ.